Literature DB >> 32010555

Silence of S1 RNA binding domain 1 represses cell growth and promotes apoptosis in human non-small cell lung cancer cells.

Tao Zhang1, Guowei Cheng2, Lei Deng1, Yin Yang1, Li Sun2, Ping Chen2, Xiangling He2, Dan Su2, Nan Bi1, Bin Qiu1.   

Abstract

BACKGROUND: To investigate the expression of S1 RNA binding domain 1 (SRBD1) in non-small cell lung cancer tissue and the effects of SRBD1 silencing on the biological behaviors of human non-small cell lung cancer cells, and to explore the molecular mechanism of SRBD1functions in human non-small cell lung cancer cells.
METHODS: Expressions of SRBD1 in human non-small cell lung cancer tissues and cell lines were examined by immunostaining and RT-PCR. shRNAs of SRBD1 were chemically synthesized and transfected into A549 and NCI-H1299 cells by lentivirus. Cell proliferation was assayed by cell counting, MTT and clone formation. Cell apoptosis was assayed by flow cytometry. Tumorigenicity was assessed by cell injection into BALB/c athymic nude mouse. Gene chip analysis was employed to explore genomic changes in A549 cells. Potential classical signaling pathways, upstream regulators and gene interaction networks were analyzed by Ingenuity Pathway Analysis, and verified by western blot analysis.
RESULTS: SRBD1 was specifically expressed in human squamous cell carcinoma and highly expressed in lung cancer cell lines, NCI-H1299, A549 and NCI-H1975. SRBD1 directed-shRNA (shSRBD1) effectively reduced the expression of SRBD1 in A549 and NCI-H1299 cells. SRBD1 silencing inhibited cell proliferation, and promoted cell apoptosis in non-small cell lung cancer cells, and suppressed tumorigenesis in a nude mouse model. In addition, we found silencing of SRBD1 expression resulted in marked changes in gene expression in A549 cells. Besides, in shSRBD1 group, the protein levels of EPS 15, IGF1R, MYC, PYCR1 and HNRNPA0 were downregulated, and the expressions of several classical factors involved in the growth and apoptosis of cancer cells were also decreased.
CONCLUSIONS: We found that SRBD1 were specifically expressed in non-small cell lung cancer tissue. Silencing of SRBD1 inhibits cell growth and promotes cell apoptosis in non-small cell lung cancer cells, and suppresses tumorigenesis in vivo, suggesting that SRBD1 may be a new diagnostic indicator and therapeutic target of non-small cell lung cancer. 2019 Translational Lung Cancer Research. All rights reserved.

Entities:  

Keywords:  S1 RNA binding domain 1 (SRBD1); apoptosis; lung adenocarcinoma; proliferation

Year:  2019        PMID: 32010555      PMCID: PMC6976381          DOI: 10.21037/tlcr.2019.10.10

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  30 in total

1.  Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES.

Authors:  Scott W Blume; Nateka L Jackson; Andra R Frost; William E Grizzle; Oleg D Shcherbakov; Hyoungsoo Choi; Zheng Meng
Journal:  Exp Mol Pathol       Date:  2010-03-15       Impact factor: 3.362

Review 2.  Cell cycle alterations and lung cancer.

Authors:  B Vincenzi; G Schiavon; M Silletta; D Santini; G Perrone; M Di Marino; S Angeletti; A Baldi; G Tonini
Journal:  Histol Histopathol       Date:  2006-04       Impact factor: 2.303

3.  Ubiquitin-mediated proteolysis of HuR by heat shock.

Authors:  Kotb Abdelmohsen; Subramanya Srikantan; Xiaoling Yang; Ashish Lal; Hyeon Ho Kim; Yuki Kuwano; Stefanie Galban; Kevin G Becker; Davida Kamara; Rafael de Cabo; Myriam Gorospe
Journal:  EMBO J       Date:  2009-03-26       Impact factor: 11.598

4.  Genome-wide association study of normal tension glaucoma: common variants in SRBD1 and ELOVL5 contribute to disease susceptibility.

Authors:  Akira Meguro; Hidetoshi Inoko; Masao Ota; Nobuhisa Mizuki; Seiamak Bahram
Journal:  Ophthalmology       Date:  2010-04-03       Impact factor: 12.079

5.  Involvement of genetic variants associated with primary open-angle glaucoma in pathogenic mechanisms and family history of glaucoma.

Authors:  Fumihiko Mabuchi; Yoichi Sakurada; Kenji Kashiwagi; Zentaro Yamagata; Hiroyuki Iijima; Shigeo Tsukahara
Journal:  Am J Ophthalmol       Date:  2014-11-18       Impact factor: 5.258

6.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

7.  Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.

Authors:  Hongkui Jin; Renhui Yang; Jed Ross; Sharon Fong; Richard Carano; Klara Totpal; David Lawrence; Zhong Zheng; Hartmut Koeppen; Howard Stern; Ralph Schwall; Avi Ashkenazi
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

8.  Proliferation enhanced by NGF-NTRK1 signaling makes pancreatic cancer cells more sensitive to 2DG-induced apoptosis.

Authors:  Yao Cheng; Dong-mei Diao; Hao Zhang; Yong-Chun Song; Cheng-Xue Dang
Journal:  Int J Med Sci       Date:  2013-03-23       Impact factor: 3.738

9.  Dogs and humans share a common susceptibility gene SRBD1 for glaucoma risk.

Authors:  Nobuyuki Kanemaki; Kissaou T Tchedre; Masaki Imayasu; Shinpei Kawarai; Masahiro Sakaguchi; Atsushi Yoshino; Norihiko Itoh; Akira Meguro; Nobuhisa Mizuki
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

10.  Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

Authors:  Anna F Farago; Long P Le; Zongli Zheng; Alona Muzikansky; Alexander Drilon; Manish Patel; Todd M Bauer; Stephen V Liu; Sai-Hong I Ou; David Jackman; Daniel B Costa; Pratik S Multani; Gary G Li; Zachary Hornby; Edna Chow-Maneval; David Luo; Jonathan E Lim; Anthony J Iafrate; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2015-12       Impact factor: 15.609

View more
  1 in total

1.  3'-daidzein sulfonate protects myocardial cells from hypoxic-ischemic injury via the NRF2/HO-1 signaling pathway.

Authors:  Xueliang Zeng; Junjian Yu; Taohui Zeng; Yuan Liu; Bei Li
Journal:  J Thorac Dis       Date:  2021-12       Impact factor: 3.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.